IL18 and neoplasm: Currently, a plethora of preclinical studies have substantiated that co-expression of cytokines such as IL-7, IL-8, IL-9, IL-12, IL-15, IL-18, IL-21, and IL-23 can augment the anti-tumor efficacy of CAR–T cells (Table 3) [179].